Literature DB >> 11195261

Olanzapine-induced leukopenia with human leukocyte antigen profiling.

N Buchman1, R D Strous, A M Ulman, M Lerner, M Kotler.   

Abstract

Olanzapine is an atypical antipsychotic medication frequently used in the management of psychotic states. While it has proved to be safe compared to clozapine with regard to haematotoxicity, because it has only been available for a few years, full documentation of its haematological side-effects remains incomplete. We report a case of olanzapine-induced leukopenia with associated neutropenia. Since clozapine-induced haematotoxicity has been associated with characteristic human leukocyte antigen (HLA) groups, HLA typing was determined in this patient. Following failure with typical antipsychotic medication, the patient received 10 mg/day of olanzapine. Three weeks later, he developed fever and a significant decrease in leukocyte count. Olanzapine was immediately discontinued. HLA typing was determined. The white cell count returned to normal and the fever, most probably secondary to the low white cell count, subsided with antibiotic treatment. HLA typing results were: A1 24, B7, B35, DRB1*15, DRB1*11, DRB3*01-03, DRB5*01-02. Olanzapine may induce serious leukopenia and neutropenia. HLA typing in this single patient demonstrated a distinct haplotype compared to that previously observed in clozapine-induced haematoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11195261     DOI: 10.1097/00004850-200101000-00007

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  2 in total

1.  Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics.

Authors:  Dora Koller; Susana Almenara; Gina Mejía; Miriam Saiz-Rodríguez; Pablo Zubiaur; Manuel Román; Dolores Ochoa; Marcos Navares-Gómez; Elena Santos-Molina; Elena Pintos-Sánchez; Francisco Abad-Santos
Journal:  Adv Ther       Date:  2020-12-05       Impact factor: 3.845

2.  Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.

Authors:  Hiroki Matsuura; Sohei Kimoto; Izumi Harada; Satoshi Naemura; Kazuhiko Yamamuro; Toshifumi Kishimoto
Journal:  BMC Psychiatry       Date:  2016-05-26       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.